📞 +1 628 258 0071(US)  📞 +44 2035 002 764(UK)
Contraceptive Drugs Market Research Report - Global Forecast till 2027

Contraceptive Drugs Market Size, Trends and Growth Outlook by Type [Oral Contraceptives (Combined Oral Contraceptive Pills and Progestogen-Only Pills), Topical Contraceptives, Contraceptive Injectables and others], Distribution Channel (Hospital & Clinics, Retail Pharmacy, Online Pharmacy and others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2027

ID: MRFR/Pharma/0768-HCR | February 2021 | Region: Global | 95 pages

Contraceptive Drugs Market Speak to Analyst Request a Free Sample

Contraceptive Drugs Market Scenario

Contraceptive Drugs Market is expected to register 6.8% CAGR during the forecast period, 2019 to 2025, with a market value of USD 16790.02 Million in 2018.

Contraceptives drugs are used to prevent pregnancy and are one of the methods used to control birth. Oral contraceptives are hormonal preparations that may contain combinations of the hormone’s estrogen and progestin or progestin alone.

The contraceptive drugs market is driven by factors such as the need to prevent the rising rate of unintended pregnancies and increasing awareness about contraceptive pills.

Additionally, the rise in government and NGO initiatives to promote contraceptive methods, easy use, and low costs of contraceptive drugs is anticipated to fuel the market growth.

For instance, according to the United Nations study ‘global perspectives on unplanned pregnancies’, globally, more than 41% of the 208 million pregnancies that occur each year are unplanned.

On the other hand, side effects associated with the use of contraceptive drugs is projected to hamper the growth of the market during the assessment period.

Moreover, major companies in the market are involved in strategic acquisitions, collaborations, mergers, and new product launch to sustain their position in the market.

For instance, in April 2018, Mylan launched generic oral contraceptive Yaz tablets, which supported the company's growth in the global market.


The contraceptive drugs market has been segmented into type, distribution channel, and region.

The global market, based on type, the market is further segmented into oral contraceptives, topical contraceptives, contraceptive injectable, and others.

The oral contraceptives segment is further bifurcated into combined oral contraceptive pills and progestogen-only pills. This segment is expected to hold a major share of the market due to easy consumption, over the counter availability of oral contraceptives, and low costs.

Based on distribution channel, the global market is segmented into hospital & clinics, retail pharmacy, online pharmacy, and others.       

The retail pharmacy segment is anticipated to be the fastest-growing segment due to the increasing over the counter purchase of contraceptive drugs.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The contraceptive drugs market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada.

The European contraceptive drugs market has been sub-divided into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

 The contraceptive drugs market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.

The contraceptive drugs market in the Middle East & Africa has been divided into the Middle East and Africa.

Key Players

The Key Players in the Global Contraceptive Drugs Market are Bayer AG (Germany), Pfizer Inc. (US), Teva Pharmaceutical Industries Ltd. (Israel), Merck & Co., Inc. (US), Mylan N.V.(US), Allergan Plc (Ireland), Agile Therapeutics (US), Piramal Enterprises Ltd. (India), GlaxoSmithKline PLC (UK), Johnson & Johnson (US), Novartis AG (Europe), and Sanofi (France).

Regional Market Summary

Global Contraceptive Drugs Market Share by Region, 2018 (%)  Contraceptive Drugs Market

Source: World Health Organization (WHO)

The market in the Americas is expected to dominate the global contraceptive drugs market due to the growing rate of unintended pregnancies and the need to prevent abortions in the region. Growing awareness about contraception in the US and Canada is expected to drive the market growth.

For example, according to an article by the National Center for Biotechnology Information, published in 2017, in the US, 45% of pregnancies are estimated to be unintended each year. Thus, to avoid abortions due to unwanted pregnancies, the use of contraceptive drugs is increasing.

The market in Asia-Pacific is expected to show a considerable amount of growth during the forecast period owing to the growing awareness about contraceptive pills and increasing government initiatives to promote contraceptive methods.

For example, in 2017, the Ministry of Health and Family Welfare of India launched two new contraceptives, a contraceptive pill ‘Chhaya’ and an injectable contraceptive MPA under the ‘Antara’ program.

The market in Europe is expected to show a considerable amount of growth, owing to the increasing number of unintended pregnancies.

The market in the Middle East & Africa is projected to account for the least share of the market due to less awareness about contraceptive drugs in the region.

Contraceptive Drugs Market, by Type

  • Oral Contraceptives

  • Combined Oral Contraceptive Pills

  • Progestogen-Only Pills

  • Topical Contraceptives

  • Contraceptive Injectable

  • Others

Contraceptive Drugs Market, by Distribution Channel

  • Hospital & Clinics

  • Retail Pharmacy

  • Online Pharmacy

  • Others

Contraceptive Drugs Market, by Region

  • Americas

    • North America

      • US

      • Canada

    • Latin America

  • Europe

    • Western Europe

      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe

    • Eastern Europe

  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific

  • Middle East & Africa

    • Middle East

    • Africa

Intended Audience

  • Research and development (R&D) companies

  • Pharmaceutical & biotechnology companies

  • Government research institutes

  • Academic institutes and universities

  • Venture capitalists

Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2018: USD 16790.02 Million
  • 2027: Significant Value
  •   CAGR   6.8% (2019-2025)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Type and Distribution Channel
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Bayer AG (Germany), Pfizer Inc. (US), Teva Pharmaceutical Industries Ltd. (Israel), Merck & Co., Inc. (US), Mylan N.V.(US), Allergan Plc (Ireland), Agile Therapeutics (US), Piramal Enterprises Ltd. (India), GlaxoSmithKline PLC (UK), Johnson & Johnson (US), Novartis AG (Europe), and Sanofi (France).
      Key Market Opportunities   increase to avoid unwanted pregnancies and their complication
      Key Market Drivers

  • rising rate of unintended pregnancies
  • increasing awareness about contraceptive pills

  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    The retail pharmacy segment would lead the market.

    The oral contraceptives segment to lead the Contraceptive Drug Market.

    The Americas have a maximum Contraceptive Drug Market.